

# Efficacy and safety of using insulin glargine 300 U/mL in patients on advanced insulin therapy with type 1 or type 2 diabetes failing to achieve their glycemic targets. The Toujeo-Neo trial.

<b>Submission date</b> 26/02/2019	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 27/02/2019	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 27/09/2022	<b>Condition category</b> Nutritional, Metabolic, Endocrine	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

All people with diabetes need insulin, either directly after diagnosis in patients with type 1 diabetes or at later disease stages in people with type 2 diabetes. There are two kind of insulin available to imitate the body's missing insulin supply: basal insulin to cover the basal need for insulin and mealtime insulin to cover the shortly elevated need after meal intake. Advanced insulin therapies using one or two shots of mealtime insulin together with basal insulin are used in long-lasting type 2 diabetes and therapies with three shots of mealtime insulin are used in long-lasting type 2 diabetes as well as in type 1 diabetes. To take insulin goes hand in hand with hypoglycemia, an unwanted state of too low blood sugar with several symptoms, sometimes even including fainting and coma. Therefore, fear of hypoglycemia often prevents people with diabetes to achieve their blood sugar targets. On the other hand it is very important for patients with diabetes to reach their blood sugar targets to avoid late-stage complications like kidney disease, eye disorders and cardiovascular diseases. Several newer types of insulins have been developed, which reduce the risk for hypoglycemia compared to older types of insulin. The aim of this study is to find out, if switching from any other basal insulin to insulin glargine 300 units per milliliter, a newer basal insulin, allows more people with type 1 or type 2 diabetes on advanced insulin therapies (using a basal and a mealtime insulin) to reach their blood sugar targets without increasing the risk of hypoglycemia in daily clinical practice.

### Who can participate?

Adults at or over the age of 18 years with type 1 or type 2 diabetes who use advanced insulin therapies (basal and mealtime insulin) and are treated by a German physician.

### What does the study involve?

Participants are elected by their treating physician to join this study, if the physician had already decided to switch their basal insulin to insulin glargine 300 units per milliliter independent of the participation in this study. Participants will be treated by their physician as usual and will visit their doctor in the usual time intervals (in Germany usually every three months for diabetes

patients). The physician will document several parameters at the first visit, when the basal insulin is switched, and at least 6 and 12 months thereafter. The study lasts one year in total. The participants are asked to answer a diabetes treatment satisfaction questionnaire at the first visit and at the visit 12 months thereafter.

What are the possible benefits and risks of participating?

There will be no immediate direct benefit or risk to those taking part, because this is a non-interventional study which means that patients are treated as they would be without participation in this study. However, the results of this study will add to the knowledge of how insulin glargine 300 units per milliliter is used in daily clinical practice and how its use in combination with mealtime insulins can be improved.

Where is the study run from?

The Toujeo-Neo study is being run by Sanofi-Aventis Deutschland GmbH and takes place in diabetologists' and general practitioners', family physicians' and internists' practices all over Germany, where people with type 1 and type 2 diabetes are treated.

When is the study starting and how long is it expected to run for?

August 2015 to March 2017

Who is funding the study?

Sanofi-Aventis Deutschland GmbH (Germany)

Who is the main contact?

Dr. Stefan Pscherer, chief physician of Clinic of Internal Medicine III, Diabetology and Nephrology, Sophien- und Hufeland-Klinikum gGmbH, Henry-van-de-Velde-Str. 2, D-99425 Weimar, Germany, email: S.Pscherer@klinikum-weimar.de

## Contact information

**Type(s)**

Scientific

**Contact name**

Dr Katrin Pegelow

**Contact details**

Sanofi-Aventis Deutschland GmbH

Potsdamer Str. 8

Berlin

Germany

D-10785

+49 (0)30 2575 2920

Katrin.Pegelow@sanofi.com

## Additional identifiers

**Clinical Trials Information System (CTIS)**

Nil known

**ClinicalTrials.gov (NCT)**

Nil known

**Protocol serial number**

GLARGL07591

## Study information

### Scientific Title

Assessment of Treatment Efficacy and Safety when switching the Basal component of any BOTplus or Basal-Bolus Regimen in Patients Failing to Reach Treatment Targets to Insulin glargine U300

### Acronym

Toujeo-Neo

### Study objectives

The aim of this non-interventional study (NIS) was to document the treatment effectiveness and safety after 6 and 12 months for diabetes patients who switched from a basal Insulin supported oral therapy with additional 1-2 prandial Insulin injections (BOTplus; type 2 diabetes mellitus) or a basal-bolus therapy (BBT; type 1 or type 2 diabetes mellitus; T1DM, T2DM) with any basal insulin other than insulin glargine 300 U/mL to a BOTplus or BBT with insulin glargine 300 U/mL under use in real-life conditions in daily clinical practice.

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

Approved 27/07/2015, Ethik-Kommission der Bayerischen Landesärztekammer/Ethical committee of the state medical council of Bavaria (Mühlbaurstr.16, D-81677, Munich; + 49 89 4147-165; ethikkommission@blaek.de), ref: 15049

### Study design

Non-interventional open-label multi-center single-arm prospective observational study

### Primary study design

Observational

### Study type(s)

Treatment

### Health condition(s) or problem(s) studied

Type 1 and type 2 diabetes mellitus in adult patients requiring insulin therapy.

### Interventions

All data were collected three times: at baseline, approximately 6 and approximately 12 months after starting insulin glargine 300 U/mL therapy. Baseline documentation (documentation 1) had to start immediately after switching to insulin glargine 300 U/mL from any other basal insulin after failing to achieve the glycemic targets on a pre-existing BOTplus (T2DM) or BBT (T1DM and T2DM) treatment. This had to occur after the physician had independently of the participation in

this study decided to prescribe insulin glargine 300 U/mL and when thereafter the physician and the patient had decided the participation of the latter in this study. Next measurements were documented approximately 6 months thereafter (documentation 2) and the last measurements were documented approximately 12 months thereafter (documentation 3). Besides this, all FBG measurements available were collected on a monthly basis asking for documentation of changes during the last four weeks each month. Also, dosing information was captured every month; i.e. actual dose and frequency of dose changes during the last four weeks. Data had to be generated during the daily clinical routine of the physicians. Any change in the patient's antidiabetic therapy regimen was strictly left at the physician's discretion. No therapeutic decision of the physician should have been based upon participation in this NIS. Titration algorithm was also left at the investigator's discretion.

Participating physicians were distributed equally all over Germany to allow for a representative sample of German T1DM and T2DM patients switching their basal insulin component of their BOTplus or BBT regimen.

In order to allow for a valid statistical analysis even in smaller subgroups of patients (as distribution within the predefined subgroups may not be equal), it was planned to document and analyze about 2,500 patients. The planned number of participating sites was 540.

Participating doctors were mostly to be diabetologists, as the kind of physician who usually follow-up basal plus prandial insulin therapy in T1DM and T2DM patients in Germany. Also, general practitioners, family physicians and internists (office based) were to be included in the study, if they treat advanced T2DM and T1DM patients. The practices were to be distributed equally all over Germany to allow for geographical representativeness.

## **Intervention Type**

Other

## **Primary outcome(s)**

Duration (persistence) of response defined as time from start of response to end of response. Beginning of response was defined by time of the first of at least two FBG values below or equal to 110 mg/dL or time of first HbA1c below or equal to predefined individual target value whichever occurred first. End of response was defined as one of the following:

- the second FBG value >110 mg/dL (>6.1 mmol/L) after start of FBG response or
- the first HbA1c value above the individual predefined target or
- change to another form of insulin therapy or change of basal insulin.

## **Key secondary outcome(s)**

1. Absolute change in HbA1c from baseline to 6 months to 12 months
2. Absolute change in FBG from baseline to 6 months to 12 months
3. Response rate 6 and 12 months after start of insulin glargine 300 U/mL treatment defined by:
  - Reaching two FBG values below or equal to 110 mg/dL or at least once the predefined individual HbA1c target value or
  - Reaching at least one HbA1c value equal or less to the predefined individual HbA1c target value OR
  - Reaching two FBG values below or equal to 110 mg/dL or
  - Reaching two FBG values below or equal to 110 mg/dL and at least once the predefined individual HbA1c target value.
4. Time from start of insulin glargine 300 U/mL treatment to response for each of the response endpoints
5. Incidence rates and rates per patient-year were calculated for symptomatic, confirmed symptomatic, nocturnal, severe, and severe nocturnal hypoglycemia as reported in the electronic Case Report Form (eCRF). Confirmation of symptomatic hypoglycemia was defined

as self-measured blood glucose (SMBG) measurement below or equal to 70 mg/dL. Severe hypoglycemia was defined as necessity of the assistance of another person or an SMBG measurement of below or equal to 56 mg/dL. Nocturnal hypoglycemia occurring during the night (approximately 10pm-6am), while the patient was asleep (symptomatic or confirmed by SMBG measurement below or equal to 70 mg/dL). Severe nocturnal hypoglycemia was defined as those nocturnal hypoglycemia fulfilling the Definition of severe hypoglycemia. 95% CIs for incidence rates were calculated according to Clopper-Pearson. Rates per patient-year were calculated as a cumulative number of hypoglycemia events for all patients divided by the cumulative duration of insulin glargine 300 U/mL therapy in years, whereas patients with missing treatment duration or missing number of hypoglycemic events were excluded.

6. Absolute change in the 4-point blood glucose profile from baseline to 6 months to 12 months

7. Absolute change in body weight from baseline to 6 months to 12 months

8. Absolute change in daily insulin doses (number of units and number of units per kg body weight [BW]) and number of dose modifications per visit.

9. Values and absolute changes for blood lipids (triglycerides, high-density Lipoprotein [HDL], low-density Lipoprotein [LDL] and total cholesterol) from baseline to 6 months to 12 months

10. Type of LLT overall and by LDL subgroups (<70 mg/dL, <100 mg/dL, 100-190 mg/dL, >190 mg/dL at respective visit). An intensification of LLT was defined as administration of an additional LLT drug compared to baseline, or a higher dosing of statin, i.e. change from moderate at one visit to intensive at a following visit.

11. Patient's treatment satisfaction, measured by using the Diabetes Treatment Satisfaction Questionnaire (DTSQs) instrument is comprised of eight items. For scoring, six of these items were summed to produce a measure of satisfaction with treatment. The remaining two items (perceived frequency of hyperglycemia and perceived frequency of hypoglycemia) were treated individually. Measured at baseline, 6 months, and 12 months.

12. Safety parameters were incidences of adverse events (AE), related AEs, serious adverse events (SAE), related SAEs and fatal AEs.

### **Completion date**

29/03/2017

## **Eligibility**

### **Key inclusion criteria**

1. Patients with type 1 diabetes (basal-bolus insulin therapy) or type 2 diabetes (basal insulin plus 1-2x prandial insulin and oral antidiabetic drugs or basal-bolus insulin therapy) with any basal insulin except insulin glargine 300 U/mL.
2. Adults and Seniors: Age at least 18 years, no upper age limit.
3. HbA1c between 7.5% to 10.0%.
4. Fasting blood glucose > 130 mg/dL.
5. Ability and willingness to perform blood glucose self-monitoring.

### **Participant type(s)**

Patient

### **Healthy volunteers allowed**

No

### **Age group**

Adult

**Lower age limit**

18 years

**Sex**

All

**Key exclusion criteria**

1. Contraindications for a therapy with insulin glargine 300 U/mL.
2. Patients receiving oral antidiabetic drug therapy only.
3. Patients receiving basal insulin and oral antidiabetic drugs without prandial insulin.
4. Patients with known cancer disease.
5. Pregnancy.
6. Drug or alcohol abuse.
7. Dementia or general incapacity to understand the content of the observational study.

**Date of first enrolment**

11/08/2015

**Date of final enrolment**

31/01/2016

**Locations****Countries of recruitment**

Germany

**Study participating centre**

Herr Dr. Stefan Pscherer

Germany

99425

**Study participating centre**

Herr Dr. Frank Ackermann

Germany

06108

**Study participating centre**

Frau Dr. Susanne Adler

Germany

33332

**Study participating centre**

**Herr Dr. Hasan Alawi**

Germany

66740

**Study participating centre**

**Herr Dr. Heiko Ambrosch**

Germany

06712

**Study participating centre**

**Frau Dr. Steffi Appelt**

Germany

97421

**Study participating centre**

**Frau Dr. Kathrin Auerbach**

Germany

04779

**Study participating centre**

**Herr Modjtaba Barghi**

Germany

12347

**Study participating centre**

**Herr Jürgen Bartlewski**

Germany

76139

**Study participating centre**

**Frau Dr. Anna BartnikMikuta**

Germany

92237

**Study participating centre**

**Herr Dr. Bert Basan**

Germany

18209

**Study participating centre**

**Herr Dr. Bernd Becker**

Germany

45355

**Study participating centre**

**Herr Dr. Sven Becker**

Germany

99085

**Study participating centre**

**Frau Dr. Kerstin Benecke**

Germany

39104

**Study participating centre**

**Herr Dr. Matthias Benecke**

Germany

06122

**Study participating centre**

**Herr Dr. Dirk Berger**

Germany

31139

**Study participating centre**

**Herr Dr. Peter Berndt**

Germany

45309

**Study participating centre**

**Herr Dr. Tasso Bieler**

Germany

01587

**Study participating centre**

**Herr Dr. Ralph Achim Bierwirth**

Germany

45138

**Study participating centre**

**Herr Igor Bolsun**

Germany

89073

**Study participating centre**

**Herr Dr. Beqir Brahim**

Germany

47906

**Study participating centre**

**Herr Dr. Markus Braun**

Germany

84489

**Study participating centre**

**Frau Dr. Daniela Brugger**

Germany

83278

**Study participating centre**

**Herr Dr. Peter Bühler**

Germany

88430

**Study participating centre**

**Herr Dr. Thomas Bulang**

Germany

02625

**Study participating centre**

**Herr Dr. Klaus Burkhardt**

Germany

91781

**Study participating centre**

**Herr Dr. Ronny Casneuf**

Germany

30880

**Study participating centre**

**Frau ReginaMonika Chmielewski**

Germany

58675

**Study participating centre**

**Frau Maren Dehne**

Germany

23879

**Study participating centre**

**Frau Dr. Iris DonatiHirsch**

Germany

44137

**Study participating centre**

**Herr Dr. Markus Eidenmüller**

Germany

35037

**Study participating centre**

**Herr Dr. Volker Eissing**

Germany

26871

**Study participating centre**

**Frau Dr. Annette Engelhardt**

Germany

99610

**Study participating centre**

**Frau Dr. Friedlinde Ernst**

Germany

87439

**Study participating centre**

**Herr Dr. FranzRudolf Fendler**

Germany

30171

**Study participating centre**

**Frau Manuela FettigKillat**

Germany

76661

**Study participating centre**

**Herr Dr. Albrecht Fießelmann**

Germany

13597

**Study participating centre**

**Herr Dr. Ulrich Flintzer**

Germany

17033

**Study participating centre**

**Herr Frank Franzmann**

Germany

32549

**Study participating centre**

**Frau Dr. Verena Fuhrmann**

Germany

07545

**Study participating centre**

**Herr Dr. Alexander Garcia Godelmann**

Germany

55130

**Study participating centre**

**Herr Dr. Gregor Gauer**

Germany

01612

**Study participating centre**

**Frau Sonja Gericke**

Germany

19348

**Study participating centre**

**Herr Dr. Peter Geßner**

Germany

76149

**Study participating centre**

**Herr Dr. Sebastian GlüerFuchs**

Germany

30900

**Study participating centre**

**Herr Dr. RainerChristian Görne**

Germany

67433

**Study participating centre**

**Herr Kai Götte**

Germany

61381

**Study participating centre**

**Herr Dr. Detlef Götze**

Germany

39120

**Study participating centre**

**Herr Volkart Güntsch**

Germany

19057

**Study participating centre**

**Herr Dirk Haaser**

Germany

01309

**Study participating centre**

**Herr Andreas Hain**

Germany

36266

**Study participating centre**

**Herr Dr. Peter Hainzinger**

Germany

85057

**Study participating centre**

**Herr Dr. Dirk Hennig**

Germany

01662

**Study participating centre**

**Frau Dr. Kerstin HerrmannBenecke**

Germany

06122

**Study participating centre**

**Herr Dr. Joachim Hesse**

Germany

19370

**Study participating centre**

**Herr Dr. Christoph Heyer**

Germany

41747

**Study participating centre**

**Frau Dr. Henrike Hilbig**

Germany

30165

**Study participating centre**

**Herr Dr. Roger Hladik**

Germany

67063

**Study participating centre**

**Herr Dr. HansDieter Hoffmann**

Germany

58706

**Study participating centre**

**Herr Dr. Gerd Hollmann**

Germany

13439

**Study participating centre**

**Frau Susanne HölzRöhrig**

Germany

55624

**Study participating centre**

**Frau Dr. Birgit HöneRömmer**

Germany

04299

**Study participating centre**

**Frau Dr. Irina Hort**

Germany

10318

**Study participating centre**

**Herr Christoph Hummel**

Germany

33602

**Study participating centre**

**Herr Dr. Michael Karl Huptas**

Germany

45307

**Study participating centre**

**Herr Dr. Sebastian Huptas**

Germany

45307

**Study participating centre**

**Herr Clemens Huth**

Germany

47929

**Study participating centre**

**Herr Professor Dr. HansDieter Janisch**

Germany

91052

**Study participating centre**

**Herr Dr. HansJoachim Jonderko**

Germany

76135

**Study participating centre**

**Herr Dr. HansPeter Kempe**

Germany

67059

**Study participating centre**

**Herr Professor Dr. Werner Kern**

Germany

89073

**Study participating centre**

**Frau Dr. Stephanie Kieu**

Germany

26388

**Study participating centre**

**Herr Dr. Andreas Kirsten**

Germany

01129

**Study participating centre**

**Herr Dr. Gerhard Klausmann**  
Germany  
63739

**Study participating centre**  
**Herr Dr. Carsten Klugewitz**  
Germany  
45277

**Study participating centre**  
**Herr Dr. Karsten Knöbel**  
Germany  
94315

**Study participating centre**  
**Frau Dr. Nicole Koch**  
Germany  
22041

**Study participating centre**  
**Herr Dr. Thorsten Koch**  
Germany  
22041

**Study participating centre**  
**Herr Andreas Kochan**  
Germany  
02826

**Study participating centre**  
**Herr Dr. Wolfgang Kohn**  
Germany  
13086

**Study participating centre**

**Frau Dr. Kerstin König**

Germany

59174

**Study participating centre**

**Herr Dr. Günter Kraus**

Germany

96117

**Study participating centre**

**Frau Katrin Krause**

Germany

06366

**Study participating centre**

**Frau Irmhild Krüger**

Germany

16928

**Study participating centre**

**Frau Dr. Kerstin Kux**

Germany

49124

**Study participating centre**

**Herr Dr. Benedict Lacner**

Germany

45468

**Study participating centre**

**Herr Dr. Bernhard Landers**

Germany

56727

**Study participating centre**

**Herr Dr. Jürgen Landschulze**  
Germany  
07768

**Study participating centre**  
**Frau Dr. Vera Lang**  
Germany  
91207

**Study participating centre**  
**Herr Hendrik Lange**  
Germany  
07570

**Study participating centre**  
**Herr Dr. Harald Letterer**  
Germany  
29459

**Study participating centre**  
**Herr Privatdozent Dr. Ulrich Lotze**  
Germany  
06556

**Study participating centre**  
**Frau Dr. Jenny LuongThanh**  
Germany  
26388

**Study participating centre**  
**Herr Dr. Lam LuongThanh**  
Germany  
26388

**Study participating centre**

**Frau Dr. Cornelia Marck**

Germany

35415

**Study participating centre**

**Herr Dr. Ekkehard Martin**

Germany

38165

**Study participating centre**

**Herr Dr. Peter Mayr**

Germany

78333

**Study participating centre**

**Herr Dr. Claus Mees**

Germany

67063

**Study participating centre**

**Frau Dr. Martina MeierHöfig**

Germany

24796

**Study participating centre**

**Frau Peggy Meyer**

Germany

13086

**Study participating centre**

**Herr Francesco Michelini**

Germany

41472

**Study participating centre**

**Herr Dr. Uwe Milbradt**

Germany

39387

**Study participating centre**

**Herr Dr. Rainer Möllmann**

Germany

47799

**Study participating centre**

**Herr Dr. Joachim Müller**

Germany

97421

**Study participating centre**

**Frau Gabriele MüllerHunold**

Germany

38368

**Study participating centre**

**Herr Dr. Axel Müllhofer**

Germany

88400

**Study participating centre**

**Frau Dr. Manuela Nader**

Germany

82110

**Study participating centre**

**Herr Dr. Rainer Naus**

Germany

87435

**Study participating centre**

**Herr Dr. Olaf Ney**

Germany

31535

**Study participating centre**

**Herr Michael Nowotny**

Germany

02763

**Study participating centre**

**Frau Dr. Katrin Ohde**

Germany

45329

**Study participating centre**

**Herr Dr. Tobias Ohde**

Germany

45329

**Study participating centre**

**Frau Dr. Silke OttoHagemann**

Germany

49377

**Study participating centre**

**Herr Dr. Andreas Patzelt**

Germany

44892

**Study participating centre**

**Herr Dr. Johannes Peters**

Germany

50126

**Study participating centre**

**Herr Dr. Gert Pfundt**

Germany

55130

**Study participating centre**

**Herr Dr. Eberhard Politz**

Germany

38518

**Study participating centre**

**Frau Maria Pollok**

Germany

58675

**Study participating centre**

**Frau Stefanie Rasfeld**

Germany

98574

**Study participating centre**

**Herr Björn Reißmann**

Germany

58730

**Study participating centre**

**Frau Dr. Uta Rieger**

Germany

14482

**Study participating centre**

**Herr Dr. Uwe Ritzel**

Germany

26384

**Study participating centre**

**Herr Dr. Tobias Rückert**

Germany

30165

**Study participating centre**

**Frau Dr. Emilia Ruff**

Germany

97980

**Study participating centre**

**Frau Dr. Ursula Ruthe**

Germany

14532

**Study participating centre**

**Herr Dr. Oliver Sauer**

Germany

02826

**Study participating centre**

**Frau Dr. Astrid Sawistowsky**

Germany

04249

**Study participating centre**

**Herr Dr. Jörg Schaper**

Germany

86470

**Study participating centre**

**Herr Privatdozent Dr. Stephan Scharla**

Germany

83435

**Study participating centre**

**Herr Edgar Schaubert**

Germany

52457

**Study participating centre**

**Herr Dr. Thomas Schaum**

Germany

23758

**Study participating centre**

**Herr Dr. Reinhard Schaupp**

Germany

97762

**Study participating centre**

**Herr Dr. Martin Scherwinski**

Germany

10823

**Study participating centre**

**Herr Alois Schießl**

Germany

22041

**Study participating centre**

**Herr Dr. Joachim Schiwietz**

Germany

49808

**Study participating centre**

**Herr Dr. Uwe Schläfer**

Germany

87439

**Study participating centre**

**Herr Oliver Schlott**

Germany

50126

**Study participating centre**

**Herr Heiko Schneider**

Germany

99510

**Study participating centre**

**Frau Dr. Stefanie Schrader**

Germany

30165

**Study participating centre**

**Frau Dr. Sabine Schulze**

Germany

35043

**Study participating centre**

**Herr Toralf Schwarz**

Germany

04442

**Study participating centre**

**Herr Dr. Andreas Schwittay**

Germany

04564

**Study participating centre**

**Frau Dr. Kathrin Seuß**

Germany

95032

**Study participating centre**

**Herr Dr. Andreas Staudenmeyer**

Germany

49808

**Study participating centre**

**Herr Dr. Jörg Steindorf**

Germany

04435

**Study participating centre**

**Frau Dorothea Stottmeister**

Germany

39307

**Study participating centre**

**Herr Dr. Kai Straßmann**

Germany

42699

**Study participating centre**

**Frau Dr. EvaMaria Streck**

Germany

04643

**Study participating centre**

**Herr Matthias Strickling**

Germany

46284

**Study participating centre**

**Frau Dr. Danuta StryjekKaminska**

Germany

65185

**Study participating centre**

**Herr Dr. Werner Stürmer**

Germany

97080

**Study participating centre**

**Herr Dr. Jörg Tafel**

Germany

61350

**Study participating centre**

**Frau Dr. Birgit Teubner**

Germany

03046

**Study participating centre**

**Herr Jörg Thelen**

Germany

15806

**Study participating centre**

**Frau Svetlana TlechasTkatsch**

Germany

14480

**Study participating centre**

**Herr Thomas Voigt**

Germany

04654

**Study participating centre**

**Herr Wolf Heinrich von Aufseß**

Germany

95445

**Study participating centre**

**Frau Dr. Heike Wagner**

Germany

47829

**Study participating centre**

**Frau Ina Walter**

Germany

99974

**Study participating centre**

**Frau Dr. Daniela Walther**

Germany

67246

**Study participating centre**

**Frau Ingrid Weber**

Germany

26725

**Study participating centre**

**Herr Dr. Norbert Weghmann**

Germany

52066

**Study participating centre**

**Herr Dr. Rolf Weißmann**

Germany

90411

**Study participating centre**

**Herr Dr. Artur Zimmermann**

Germany

83043

**Study participating centre**

**Herr Dr. Stefan Zinn**

Germany

36341

**Study participating centre**

**Herr Dr. Jens Abendroth**

Germany

06188

## Sponsor information

**Organisation**

Sanofi-Aventis Deutschland GmbH

**ROR**

<https://ror.org/03ytdtb31>

## Funder(s)

**Funder type**

Industry

**Funder Name**

Sanofi-Aventis Deutschland GmbH

## Results and Publications

**Individual participant data (IPD) sharing plan**

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request

**IPD sharing plan summary**

Available on request

**Study outputs**

**Output type**

**Details**

Pscherer S, Fritsche A, Anderten H, Pegelow K, Seufert J, Pfohl M.  
Switching to Insulin Glargine 0 U/mL (Gla-0) after Failure of Advanced

**Date created**   **Date added**   **Peer reviewed?**   **Patient-facing?**

[Abstract](#)

23/06

<a href="#">results</a>	Insulin Therapy (IT) with Other Basal Insulins (BI) in Patients (Pts) with Type 2 Diabetes (T2DM) Improved Glycemic Control. Diabetes 2018; 67 (Suppl. 1): Abstract 2288-PUB (Published only). Available at:	/2018	No	No	
<a href="#">Poster results</a>	Pscherer S, Pfohl M, Anderten H, Pegelow K, Seufert J. Nicht-interventionelle Studie zur Untersuchung der Effizienz des Wechsels der Basalinsulinkomponente bei einer BOTplus oder intensivierten Insulintherapie (ICT) zu Insulin glargin 0 E/ml bei Typ-1- und Typ-2-Diabetespatienten mit inadäquater glykämischer Kontrolle. Diabetologie & Stoffwechsel 2016; 11 (Suppl. 1): Abstr. P220. Presented as poster at the 51st Annual Meeting of the German Diabetes Association (DDG) at 05.05.2016 in Berlin, Germany. Available at:	05/05 /2016	No	No	
<a href="#">Poster results</a>	Fritsche A, Pscherer S, Pfohl M, Anderten H, Pegelow K, Seufert J. Umstellung des Basalinsulins auf Insulin glargin 0 E/ml (Gla-0) nach Versagen der Basis-Bolus-Therapie (ICT) mit einem anderen Basalinsulin verbesserte bei Typ-1-Diabetespatienten die Blutzucker-Einstellung – 6-Monats-Ergebnisse der Toujeo-Neo-T1DM-Studie. Diabetologie & Stoffwechsel 2018; 13 (Suppl. 1): S61, Abstract P181. Presented as poster at the 53rd Annual Meeting of the German Diabetes Association (DDG) at 11.05.2018 in Berlin, Germany. Available at:	11/05 /2018	No	No	
<a href="#">Poster results</a>	Pscherer S, Pfohl M, Fritsche A, Anderten H, Pegelow K, Seufert J. Umstellung des Basalinsulins auf Insulin glargin 0 E/ml (Gla-0) nach Versagen einer Basis-Bolus- (ICT) oder einer basalunterstützten oralen Therapie mit einmal täglich prandialem Insulin (BOTplus) mit einem anderen Basalinsulin verbesserte bei Typ-2-Diabetespatienten die glykämische Kontrolle – 6-Monats-Ergebnisse der Toujeo-Neo-T2DM-Studie. Diabetologie & Stoffwechsel 2018; 13 (Suppl. 1): S51-S52, Abstract P153. Presented as poster at the 53rd Annual Meeting of the German Diabetes Association (DDG) at 11.05.2018 in Berlin, Germany. Available at:	11/05 /2018	No	No	
<a href="#">Poster results</a>	Fritsche A, Pscherer S, Anderten H, Pegelow K, Seufert J, Pfohl M. Switching to Insulin Glargine 0 U/mL (Gla-0) Improves Glycemic Control After Failure of Basal-Bolus Therapy (BBT) With Other Basal Insulins (BI) in patients (pts) with Type 1 Diabetes (T1DM). Diabetes 2018; 67 (Suppl. 1): Abstract 1031-P. Presented as poster at the 78th Scientific Sessions of the American Diabetes Association at 23.06.2018 in Orlando, FL, USA. Available at:	23/06 /2018	No	No	
<a href="#">Protocol file</a>	version 1.0	06/05 /2015	27/09 /2022	No	No